An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron
Baoxue Quan(Sichuan University), Shengyong Yang(Sichuan University), Renjie Zhou(Chinese University of Hong Kong), Chaemin Yoon(University of Hong Kong), Mingxin Chen(Sichuan University), Huiping Shuai(University of Hong Kong), Hin Chu(University of Hong Kong), Jasper Fuk‐Woo Chan(Hong Kong Science and Technology Parks Corporation), Ming Wu(Jinan University), Anjie Xia(Sichuan University), Yuxin Hou(University of Hong Kong), Jian Lei(Sichuan University), Falu Wang(Sichuan University), Guifeng Lin(Sichuan University), Kwok‐Yung Yuen(University of Hong Kong - Shenzhen Hospital), Yifei Wang(Southwest Medical University), Weimin Li(Sichuan University), Shiyu Zhang(Hainan Medical University), Kai Wang(Sichuan University), Xinlei Liu(Chongqing University), Chong Huang(Sichuan University), Wei Yang(Sichuan University), Rui Zeng(Sichuan University), Chenyu Tian(Sichuan University), Jingxin Qiao(Sichuan University), Terrence Tsz‐Tai Yuen(Sichuan University), Wenpei Li(Sichuan University)
Cited by 101
Related Papers
A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster
|The Lancet|2020|9.6k
Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study
|The Lancet Infectious Diseases|2020|3.4k
Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan
|Emerging Microbes & Infections|2020|3.3k
Consistent Detection of 2019 Novel Coronavirus in Saliva
|Clinical Infectious Diseases|2020|2k